GSK Strengthens Allergy Portfolio, Acquiring RAPT for $2.2 Billion at $58 Per Share

GSK is acquiring RAPT Therapeutics for approximately $2.2 billion, with a focus on enhancing its portfolio in respiratory and immunology treatments, particularly through the development of ozureprubart for food allergies.